The ASRM 2024 Featured Jobs Guide is live!

Menu
Close Close Icon

Repetitive oocyte donation: a committee opinion (2020)


Donors should be advised of the number of cycles/donations that a given oocyte donor may undergo. Although existing data cannot permit conclusive recommendations, concern for the issues of safety and well-being of oocyte donors warrants consideration. 
 
Donor cycles are relatively common in assisted reproductive technology (ART), and the number of donor cycles using fresh and frozen oocytes was more than 7,800 cycles in 2016 in the United States (1). Women may choose to donate oocytes more than one time, giving rise to concerns about the optimal number of times that each woman should donate, both to protect the health of the donor and to avoid issues of consanguinity. This discussion will address the issue of whether limits should be advised on the number of cycles/donations that a given oocyte donor may undergo. Although existing data cannot permit conclusive recommendations, concern for the safety and the well-being of oocyte donors warrants consideration. 
 
The practice of oocyte donation has potential risks for the donor, including the risks associated with ovarian stimulation, the oocyte retrieval procedure, and anesthesia, among others. Although the recipient derives a clear and tangible benefit from oocyte donation, the donor derives benefit only through a sense of altruism and/or financial compensation for her services. Therefore, the question arises of whether the number of times that a given oocyte donor might donate her gametes should be limited. Despite the absence of definitive, long-term follow-up data, there has nonetheless been motivation on the part of ART practitioners to develop a consensus for a prudent approach. Unusual circumstances should be considered on an individual basis before surpassing the maximum number of donations proposed by these suggested limits.  

RISKS OF INADVERTENT CONSANGUINITY 

Inadvertent consanguinity resulting from oocyte donation could occur if a given donor has donated to two or more unrelated families and the offspring are unaware of their specific genetic heritage. Previous documents on donor insemination published by the American Society for Reproductive Medicine (ASRM) and others have advised informing offspring that they are the product of donated gametes and maintaining a limit of no more than 25 pregnancies per sperm donor in a catchment area of 800,000 residences to minimize the risk of consanguinity (2–4). Subsequent studies have commented that additional factors, including the lifting of donor anonymity, genetic carrier screening, and social changes in mobility and attitude, could further reduce the risk of inadvertent consanguinity (5–7). Given that oocyte donation is a complex process and may result in cryopreserved oocytes, embryos, and an unpredictable number of pregnancies over a long period of time and a wide geographical region, it is reasonable to also limit the number of oocyte donations rather than the number of resulting pregnancies. The suggestions outlined here may require modification if the population using donor gametes represents an isolated subgroup or the specimens are distributed over a particularly small geographic area.  

HEALTH RISKS TO THE OOCYTE DONOR 

Ovarian Stimulation 

Ovarian stimulation entails both known and potential risks. The risk of severe  ovarian  hyperstimulation syndrome (OHSS) is reported to be approximately 1% to 2% per retrieval cycle. The incidence and severity of OHSS may in fact be lower in oocyte donors (8), in part owing to the absence of conception after stimulation. The use of a gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation compared with the traditional use of human chorionic gonadotropin (hCG) has been shown to dramatically reduce the risk of developing OHSS in oocyte donors in both large retrospective and smaller prospective studies (9–12).  

Acute Procedural Risks 

There are real, albeit small (<0.5%), risks of acute complications, including pelvic infection, intraperitoneal hemorrhage, or ovarian torsion (9, 13, 14). The risks associated with the low levels of anesthesia generally employed for oocyte retrieval in a young, healthy population should be very small. However, idiosyncratic reactions to anesthetic agents and other anesthetic complications (e.g., aspiration) may occur.  

Cancer 

The preponderance of data does not demonstrate an association between the use of ovarian-stimulation agents and cancer, including invasive ovarian and breast cancers (15–17). Moreover, the current understanding of the pathogenesis of ovarian cancer is rapidly evolving, calling into question traditional theories of the relationship between nulliparity and ovarian cancer (18).  

Future Ovarian Reserve of the Donor 

It is not presently known whether repetitive follicular aspirations affect the donor's future ovarian reserve. However, the physiologic mechanism of oocyte recruitment in ovarian stimulation is a reduction in follicles destined for atresia. Preliminary data indicate that repetitive and multiple cycles of oocyte donation do not decrease the donor's ovarian reserve, as assessed by serum antimullerian hormone levels (19).  

Psychological Risks 

Oocyte donation may entail potential psychological risks (ambivalence, regret, etc.) that might occur around the time of the procedure or years later.
 

Loss of Intended Anonymity 

Direct-to-consumer DNA testing, genealogy databases, and social media offer the opportunity to identify genetic connections to relatives with whom a consumer may or may not have a personal relationship. Despite the intention of anonymity, egg donors should be counseled that their anonymity could be compromised if their DNA or that of a close relative is added to a database. Although donors have control over their own participation in direct-to-consumer DNA testing, relatives of donors and donor-conceived offspring who choose to participate may find themselves linked. This may permit the recipient or donor-conceived offspring to deduce the identity of the donor, leading to unanticipated contact with children conceived from their gametes in the future. These issues should be addressed during appropriate pretreatment screening and counseling (20).  

RISK ASSESSMENT: MAXIMUM NUMBER OF CYCLES PER OOCYTE DONOR 

Previous expert opinion has suggested a limit of six cycles per donor (21–24), a recommendation that this document continues to support. The basis for this recommendation is rooted in a concern over the potential cumulative risk accrued after a donor undergoes six ovarian-stimulation and egg-retrieval procedures. In a single ovarian-stimulation cycle, the donor’s risk of severe OHSS is reported to be approximately 1% to 2% per retrieval cycle, and the risk of acute complications, including pelvic infection, intraperitoneal hemorrhage, or ovarian torsion, is estimated at <0.5%. Cumulatively, after six donation cycles, these risks to an individual donor aggregate to an overall risk of 8% to 13% of a serious adverse event, recognizing that this will vary among individuals. Further, it is reasonable to assume that some egg donors will require fertility services themselves, including in vitro fertilization, at a rate proportional to the general population stratified by age. Therefore, it may be prudent to limit the number of stimulated cycles for an individual donor to no more than six.  

SUMMARY 

  • Oocyte donors are exposed to the risks attendant to ovarian stimulation, oocyte retrieval, and anesthesia. 
  • Severe OHSS is estimated to occur in 1% to 2% of donation cycles, but the risk may be further reduced by the use of GnRH agonists for triggering final oocyte maturation. 
  • The risk of serious acute complications associated with these procedures is small (<0.5%). 
  • The preponderance of data does not demonstrate a significant risk of future cancers in women undergoing stimulation and egg retrieval. 
  • The data are limited, but available evidence does not suggest that oocyte donation is associated with changes in the donor's ovarian reserve.  


CONCLUSION 

Currently, there are no clearly documented long-term risks associated with oocyte donation, and as such, no definitive data upon which to base absolute recommendations. Furthermore, there is a paucity of long-term follow-up data for repeat oocyte donors. However, because of the possible cumulative risks to and future needs of an individual donor, as outlined in the preceding discussion, it may be reasonable and prudent to limit the number of stimulated cycles for a given oocyte donor to no more than six. These recommendations will inevitably be modified as new data become available. 


Acknowledgments: This report was developed under the direction of the Practice Committee of the American Society for Reproductive Medicine (ASRM) in collaboration with the Society for Assisted Reproductive Technology (SART) as a service to its members and other practicing clinicians. Although this document reflects appropriate management of a problem encountered in the practice of reproductive medicine, it is not intended to be the only approved standard of practice or to dictate an exclusive course of treatment. Other plans of management may be appropriate, taking into account the needs of the individual patient, available resources, and institutional or clinical practice limitations. The Practice Committees and the Board of Directors of ASRM and SART have approved this report. 
 
This document was reviewed by ASRM members, and their input was considered in the preparation of the final document. The Practice Committee acknowledges the special contribution of Anthony Propst, M.D., in the preparation of this document. The following members of the ASRM Practice Committee participated in the development of this document. All Committee members disclosed commercial and financial relationships with manufacturers or distributors of goods or services used to treat patients. Members of the Committee who were found to have conflicts of interest based on the relationships disclosed did not participate in the discussion or development of this document. 
 
Alan Penzias, M.D.; Ricardo Azziz, M.D., M.P.H., M.B.A.; Kristin Bendikson, M.D.; Samantha Butts, M.D., M.S.C.E.; Tommaso Falcone, M.D.; Susan Gitlin, Ph.D.; Clarisa Gracia, M.D., M.S.C.E.; Karl Hansen, M.D., Ph.D.; Micah Hill, D.O.; William Hurd, M.D., M.P.H.; Sangita Jindal, Ph.D.; Suleena Kalra, M.D., M.S.C.E.; Jennifer Mersereau, M.D.; Randall Odem, M.D.; Robert Rebar, M.D.; Richard Reindollar, M.D.; Catherine Racowsky, Ph.D.; Mitchell Rosen, M.D.; Jay Sandlow, M.D.; Peter Schlegel, M.D.; Anne Steiner, M.D., M.P.H.; Dale Stovall, M.D.; and Cigdem Tanrikut, M.D.  

REFERENCES 

  1. Society for Assisted Reproductive Technology. Clinic Summary Report 2015. Available at: https://www.sartcorsonline.com/rptCSR_PublicMultYear. aspx?reportingYear¼2016. 
  2. De Boer A, Oosterwijk JC, Rigters-Aris CA. Determination of a maximum number of artificial inseminations by donor children per sperm donor. Fertil Steril 1995;63:419–21. 
  3. Curie-Cohen M. The frequency of consanguineous matings due to multiple use of donors in artificial insemination. Am J Hum Genet 1980;32:589–600. 
  4. Practice Committee of the American Society for Reproductive Medicine. Guidelines for therapeutic donor insemination. Fertil Steril 1998;70:1–4. 
  5. Ethics Committee of the American Society for Reproductive Medicine. Informing offspring of their conception by gamete or embryo donation: an Ethics Committee opinion. Fertil Steril 2018;109:601–5. 
  6. Janssens PM. No reason for a reduction in the number of offspring per sperm donor because of possible transmission of autosomal dominant diseases. Hum Reprod 2003;18:669–71. 
  7. Sawyer N, McDonald J. A review of mathematical models used to determine sperm donor limits for infertility treatment. Fertil Steril 2008;90:265–71. 
  8. Sauer MV, Paulson RJ, Lobo RA. Rare occurrence of ovarian hyperstimulation syndrome in oocyte donors. Int J Gynaecol Obstet 1996;52:259–62. 
  9. Bodri D, Guillen JJ, Polo A, Trullenque M, Esteve C, Coll O. Complications related to ovarian stimulation and oocyte retrieval in 2052 oocyte donor cycles. Reprod Biomed Online 2008;17:237–43. 
  10. Galindo A, Bodri D, Guillen JJ, Colodron M, Vernaeve V, Coll O. Ovulation triggering with GnRH agonist vs. hCG in the same egg donor population undergoing donor oocyte cycles with GnRH antagonist: a prospective randomized cross-over trial. J Assist Reprod Genet 2009;26:251–6. 
  11. Melo M, Busso CE, Bellver J, Alama P, Garrido N, Meseguer M, et al. GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study. Reprod Biomed Online 2009;19:486–92. 
  12. Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertil Steril 2016;106:1634–47. 
  13. Bennett SJ, Waterstone JJ, Cheng WC, Parsons J. Complications of transvaginal ultrasound-directed follicle aspirations: a review of 2670 consecutive procedures. J Assist Reprod Genet 1993;10:72–7. 
  14. Ludwig AK, Glawatz M, Griesinger G, Diedrich K, Ludwig M. Perioperative and post-operative complications of transvaginal ultrasound-guided oocyte retrieval: prospective study of >1000 oocyte retrievals. Hum Reprod 2006; 21:3235–40. 
  15. Venn A, Watson L, Lumley J, Giles G, King C, Healy D. Breast and ovarian cancer incidence after infertility and in vitro fertilization. Lancet 1995;346: 995–1000. 
  16. Brinton LA, Sahasrabuddhe VV, Scoccia B. Fertility drugs and the risk of breast and gynecologic cancers. Semin Reprod Med 2012;30:131–45. 
  17. Practice Committee of the American Society for Reproductive Medicine. Fertility drugs and cancer: a guideline. Fertil Steril 2016;106:1617–26. 
  18. Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011;11:719–25. 
  19. Bukulmez O, Li Q, Carr BR, Leader B, Doody KM, Doody KJ. Repetitive oocyte donation does not decrease serum anti-mu€llerian hormone levels. Fertil Steril 2010;94:905–12. 
  20. Harper JC, Kennett D, Reisel D. The end of donor anonymity: how genetic testing is likely to drive anonymous gamete donation out of business. Hum Reprod 2016;31:1135–40. 
  21. Practice Committee of the American Society for Reproductive Medicine and Practice Committee of the Society for Assisted Reproductive Technology. Repetitive oocyte donation: a committee opinion. Fertil Steril 2014;102:964–6. 
  22. Practice Committee of American Society for Reproductive Medicine. Repetitive oocyte donation. Fertil Steril 2008;90(Suppl):S194–5. 
  23. Practice Committee of the American Society for Reproductive Medicine. Repetitive oocyte donation. Fertil Steril 2006;86(Suppl):S216–7. 
  24. Practice Committee of the American Society for Reproductive Medicine. Repetitive oocyte donation. Fertil Steril 2004;82(Suppl):S158–9. 

Practice Documents

ASRM Practice Documents have been developed to assist physicians with clinical decisions regarding the care of their patients.
PracticeDocument_Teaser.webp

The use of preimplantation genetic testing for aneuploidy: a committee opinion (2024)

PGT-A use in the U.S. is rising, but its value as a routine IVF screening test is unclear, with mixed results from various studies.
PracticeDocument_Teaser.webp

Evidence-based diagnosis and treatment for uterine septum: a guideline (2024)

To provide evidence-based recommendations regarding the diagnosis and effectiveness of surgical treatment of a uterine septum.
PracticeDocument_Teaser.webp

The use of hormonal contraceptives in fertility treatments: a committee opinion (2024)

Hormonal contraception aids in the timing of ART cycles, reduce ovarian cysts at IVF cycle initiation, and optimize visualization before hysteroscopy.
Practice Committee Documents teaser

Current evaluation of amenorrhea: a committee opinion (2024)

Amenorrhea is the absence or abnormal cessation of the menses.

More Resources

MAC 2021 teaser
ASRM Academy on the Go

ASRM MAC Tool 2021

The ASRM Müllerian Anomaly Classification 2021 (MAC2021) includes cervical and vaginal anomalies and standardize terminology within an interactive tool format.

View the MAC Tool
EMR Phrases teaser
Practice Guidance

EMR Shared Phrases/Template Library

This resource includes phrases shared by ASRM physician members to provide a template for individuals to create their own EMR phrases.

View the library
Practice Committee Documents teaser

ASRM Practice Documents

These guidelines have been developed by the ASRM Practice Committee to assist physicians with clinical decisions regarding the care of their patients.

View ASRM Practice Documents
Ethics Committee teaser

ASRM Ethics Opinions

Ethics Committee Reports are drafted by the members of the ASRM Ethics Committee on the tough ethical dilemmas of reproductive medicine.

View ASRM Ethics Opinions
Coding Corner general teaser
Practice Guidance

Coding Corner Q & A

The Coding Corner Q & A is a list of previously submitted and answered questions from ASRM members about coding. Answers are available to ASRM Members only.

View the Q & A
Covid-19 teaser
Practice Guidance

COVID-19 Resources

A compendium of ASRM resources concerning the Novel Corona virus (SARS-COV-2) and COVID-19.

View the resources
Couple looking at laptop for online patient education materials

Patient Resources

ReproductiveFacts.org provides a wide range of information related to reproductive health and infertility through patient education fact sheets, infographics, videos, and other resources.

View Website

Topic Resources

View more on the topic of egg donation
Videos Icon

Hormonal Induction of Endometrial Receptivity for Fresh or Frozen Embryo Transfer​ Part I

Explore Dr. Paulson's insights on endometrial receptivity and hormonal preparation in IVF, egg donation, and surrogacy, highlighting estrogen and progesterone roles. View the ASRMed Talk Video
Coding Icon

Mental health assessment for donors and intended parents

Is it appropriate to use 96156 or 96167 for mental health professional (MHP) counseling of gamete/embryo donors and gestational carriers? View the Answer
Document Icon

Family members as gamete donors or gestational carriers: an Ethics Committee opinion (2024)

The use of adult intrafamilial gamete donors and gestational surrogates is ethically acceptable when all participants are fully informed and counseled. View the Committee Document
Coding Icon

Diagnosis code for donation

What is the diagnosis code for an embryo donation versus egg donation? View the Answer
Coding Icon

Mandated states and egg retrieval

What name should you use to submit for reimbursement for the actual egg donor when there is benefit for the donor egg retrieval? View the Answer
Coding Icon

Reimbursement for donor egg

My wife and I are going through a fertility treatment process, and we have purchased a donor egg out-of-pocket from a donor bank.  View the Answer
Videos Icon

Modernizing Clinic Options for Directed Gamete and Embryo Donation

Explore the evolution of gamete insemination laws, ethics, and rights for donor-conceived individuals from 1884 to present-day privacy shifts. View the ASRMed Talk Video
Document Icon

Misconduct in third-party assisted reproductive technology by participants and nonmedical professionals or entities: an Ethics Committee opinion (2023)

In some instances, it is ethically permissible for the physician to either disclose material information to the affected party or to decline to provide or continue to provide care. View the Committee Opinion
Coding Icon

Reimbursement for cost of donor egg

My wife and I are going through a fertility treatment process, and we have purchased a donor egg out-of-pocket from a donor bank.  View the Answer
Coding Icon

Billing egg donor’s retrieval to recipient’s insurance

How you would bill an egg donor’s retrieval to a patient’s insurance? View the Answer
Coding Icon

Psychological Evaluation

Many REs require patients (and their spouses/partners) who are considering using donor gametes to see an infertility counselor first. View the Answer
Coding Icon

IVF Case Rates

What ICD-10 codes apply to case rates? View the Answer
Coding Icon

Diagnosis Code For Same-Sex Egg Donation

We have a same-sex male couple with insurance coverage for IVF.  View the Answer
Coding Icon

Donor Egg Infectious Disease Lab Screening

The issue we are experiencing is outside labs billing with Z11.3 are getting denials stating improper ICD-10 for the services billed.  View the Answer
Coding Icon

Donor Egg Lot Acquisition

What is the code for egg lot acquisition? View the Answer
Coding Icon

Donor Eggs-Physical Exam

Is there a specific CPT code used for Donor Physical Exams or would a practice just bill using the appropriate E&M Code?  View the Answer
Coding Icon

Donor Egg-Retrieval On Recipient's Claim

Is the donor egg retrieval included on the bill to insurance with the first IVF treatment for the recipient?  View the Answer
Coding Icon

Donor Embryos

Could you give guidance for the correct ICD-10 code(s) to use when a patient is doing an Anonymous Donor Embryo Transfer cycle? View the Answer
Coding Icon

Donor Screening

Is there a specific CPT code used for Donor Physical Exams or would a practice just bill using the appropriate E&M Code?  View the Answer
Coding Icon

Egg Culture and Fertilization: Same Gender

A same-sex male couple requested half their donor eggs be fertilized with sperm from male #1 and the other half fertilized from male #2. View the Answer
Coding Icon

Claim Form for Donor Egg Retrieval

What bill form is used of IVF donor egg retrieval? View the Answer
Coding Icon

Coding For Donor Egg Retrieval For Male Intended Parent

In coding a donor-egg retrieval to bill to insurance under the male intended parent, would it be appropriate to use the Z31.83?  View the Answer
Document Icon

Updated terminology for gamete and embryo donors: directed (identified) to replace ‘‘known’’ and nonidentified to replace ‘‘anonymous’’: a committee opinion (2022)

ASRM encourages all stakeholders with an interest in gamete and embryo donation to adopt directed (identified). View the Committee Opinion
Document Icon

Financial compensation of oocyte donors: an Ethics Committee opinion (2023)

Financial compensation of women donating oocytes for reproductive or research purposes is justified on ethical grounds. View the Committee Opinion
Document Icon

Guidance regarding gamete and embryo donation (2021)

This document provides the latest recommendations for the evaluation of potential sperm, oocyte, and embryo donors as well as their recipients. View the Committee Opinion
Document Icon

Evidence-based outcomes after oocyte cryopreservation for donor oocyte in vitro fertilization and planned oocyte cryopreservation: a guideline (2021)

A review of success rates, factors that may impact success rates, and  outcomes. View the Committee Opinion
Document Icon

Oocyte or embryo donation to women of advanced reproductive age: an Ethics Committee opinion (2016)

Advanced reproductive age (ARA) is a risk factor for female infertility, pregnancy loss, fetal anomalies, stillbirth, and obstetric complications.  View the Committee Opinion